Rivera Jose E 4

Accession 0001209191-21-024888

CIK 0001652130other

View on SEC.gov Company Profile

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 8:42 PM ET

Size

61.9 KB

Accession

0001209191-21-024888

Insider Transaction Report

Form 4

Period: 2021-04-01

Intellia Therapeutics, Inc.NTLA

Rivera Jose E

Chief Operating & Legal Offr10% Owner

Transactions

Exercise/Conversion
Common Stock
2021-04-01$13.88/sh+33,000$458,040→ 148,842 total
Sale
Common Stock
2021-04-01$83.91/sh−3,234$271,365→ 132,099 total
Sale
Common Stock
2021-04-01$81.83/sh−4,818$394,257→ 145,958 total
Sale
Common Stock
2021-04-01$83.72/sh−1,724$144,333→ 141,506 total
Exercise/Conversion
Common Stock
2021-04-01$14.58/sh+10,000$145,800→ 150,543 total
Sale
Common Stock
2021-04-01$80.73/sh−700$56,511→ 149,843 total
Sale
Common Stock
2021-04-01$83.98/sh−1,049$88,095→ 145,199 total
Exercise/Conversion
Common Stock
2021-04-01$6.83/sh+33,001$225,397→ 178,077 total
Sale
Common Stock
2021-04-01$80.85/sh−1,965$158,870→ 176,112 total
Sale
Common Stock
2021-04-01$85.76/sh−124$10,634→ 162,388 total
Exercise/Conversion
Stock Option (right to buy)
2021-04-01−21,000→ 29,090 total
Exercise: $18.30Exp: 2027-12-11→ Common Stock (21,000 underlying)
Exercise/Conversion
Stock Option (right to buy)
2021-04-01−33,001→ 6,116 total
Exercise: $6.83Exp: 2026-02-02→ Common Stock (33,001 underlying)
Sale
Common Stock
2021-04-01$81.89/sh−8,266$676,903→ 138,566 total
Sale
Common Stock
2021-04-01$81.95/sh−2,644$216,676→ 147,199 total
Sale
Common Stock
2021-04-01$82.87/sh−951$78,809→ 146,248 total
Sale
Common Stock
2021-04-01$85.14/sh−123$10,472→ 145,076 total
Sale
Common Stock
2021-04-01$81.87/sh−6,768$554,096→ 169,344 total
Sale
Common Stock
2021-04-01$82.77/sh−3,361$278,190→ 165,983 total
Sale
Common Stock
2021-04-01$84.73/sh−1,213$102,777→ 162,512 total
Exercise/Conversion
Stock Option (right to buy)
2021-04-01−10,000→ 51,000 total
Exercise: $14.58Exp: 2028-12-17→ Common Stock (10,000 underlying)
Sale
Common Stock
2021-04-01$80.79/sh−2,010$162,388→ 146,832 total
Sale
Common Stock
2021-04-01$82.63/sh−2,728$225,415→ 143,230 total
Sale
Common Stock
2021-04-01$83.85/sh−2,258$189,333→ 163,725 total
Exercise/Conversion
Stock Option (right to buy)
2021-04-01−33,000→ 39,000 total
Exercise: $13.88Exp: 2027-01-05→ Common Stock (33,000 underlying)
Sale
Common Stock
2021-04-01$82.76/sh−3,233$267,563→ 135,333 total
Sale
Common Stock
2021-04-01$84.94/sh−1,067$90,631→ 131,032 total
Exercise/Conversion
Common Stock
2021-04-01$18.30/sh+21,000$384,300→ 152,032 total
Sale
Common Stock
2021-04-01$80.82/sh−1,256$101,510→ 150,776 total
Sale
Common Stock
2021-04-01$84.87/sh−963$81,730→ 140,543 total

Holdings

Common Stock
(indirect: See Footnote)
262,210

Footnotes (25)

[F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.37 to $84.17, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F11]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.43, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.44 to $81.415, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F13]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.52 to $82.46, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F14]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.605 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F15]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.69 to $84.57, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F16]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.3925 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F17]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.4025 to $82.385, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F18]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.415 to $83.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F19]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.50, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.35 to $81.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F20]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.55 to $85.29, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F21]Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares.
[F22]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 115,000 shares as of April 1, 2021.
[F23]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 58,906 shares as of April 1, 2021.
[F24]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 39,937 shares as of April 1, 2021.
[F25]The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 175,117 shares as of April 1, 2021.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.39 to $82.375, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3975 to $83.28, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.455 to $84.45, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.535 to $85.38, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.305 to $81.16, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.31 to $82.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.3175 to $82.92, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2021 at each separate price.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Intellia Therapeutics, Inc.

CIK 0001652130

→

Entity typeother

Related Parties

filerCIK 0001671870

Filing Metadata

Form type: 4
Filed: Apr 1, 8:00 PM ET
Accepted: Apr 2, 8:42 PM ET
Size: 61.9 KB

View on SEC.gov